Inventory decreased 28.9%
Inventory changed -28.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Inventory changed -28.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed -34.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Total assets changed -38.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Trade receivables changed -72.1% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating cash flow changed +105.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. Relative percentage is de-emphasized because the comparison has a sign change. This reverses 2 consecutive comparable moves in the opposite direction.
Revenue changed -62.4% from the comparable as-filed period.
Operating margin changed -15992 basis points from the comparable as-filed period.
Net income changed -575.6% from the comparable as-filed period.
Gross margin changed -6741 basis points from the comparable as-filed period.
Shares outstanding changed +53.4% from the comparable as-filed period. The change ranks at the 50th percentile of 8 prior comparable changes.
Operating income changed -1419.1% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a low base.
Inventory / revenue changed +42619 basis points from the comparable as-filed period.
SBC / revenue changed +2478 basis points from the comparable as-filed period.
R&D / revenue changed +717 basis points from the comparable as-filed period.
Receivables / revenue changed -1946 basis points from the comparable as-filed period.
Operating cash-flow margin changed +1688 basis points from the comparable as-filed period.
Research & development changed -12.3% from the comparable as-filed period.
Stock-based compensation changed -12.0% from the comparable as-filed period.
Gross profit changed -136.2% from the comparable as-filed period. Relative percentage is de-emphasized because the comparison has a sign change.
Cash & equivalents changed +4.6% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.